LUMINARI, Stefano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 31.298
EU - Europa 13.260
AS - Asia 13.099
SA - Sud America 2.088
AF - Africa 323
OC - Oceania 89
Continente sconosciuto - Info sul continente non disponibili 10
Totale 60.167
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 30.750
GB - Regno Unito 4.332
CN - Cina 3.458
SG - Singapore 3.440
IT - Italia 2.488
DE - Germania 1.826
HK - Hong Kong 1.774
BR - Brasile 1.577
VN - Vietnam 1.507
SE - Svezia 1.070
FI - Finlandia 796
BD - Bangladesh 584
RU - Federazione Russa 572
FR - Francia 531
UA - Ucraina 524
TR - Turchia 472
KR - Corea 378
CA - Canada 286
IN - India 281
BG - Bulgaria 232
AR - Argentina 198
ID - Indonesia 198
JP - Giappone 176
NL - Olanda 167
MX - Messico 133
IQ - Iraq 125
ES - Italia 103
IE - Irlanda 102
ZA - Sudafrica 90
AE - Emirati Arabi Uniti 87
EC - Ecuador 84
IL - Israele 84
PL - Polonia 83
AU - Australia 80
PK - Pakistan 79
MA - Marocco 67
AT - Austria 65
CO - Colombia 61
CH - Svizzera 52
EG - Egitto 52
SA - Arabia Saudita 47
VE - Venezuela 44
CL - Cile 42
MY - Malesia 41
BE - Belgio 39
PH - Filippine 39
PT - Portogallo 39
LT - Lituania 38
UZ - Uzbekistan 38
JO - Giordania 34
TH - Thailandia 34
CZ - Repubblica Ceca 31
IR - Iran 30
KE - Kenya 30
PY - Paraguay 30
TW - Taiwan 29
RO - Romania 28
NP - Nepal 25
BZ - Belize 23
DZ - Algeria 23
AZ - Azerbaigian 21
CR - Costa Rica 19
DO - Repubblica Dominicana 18
PE - Perù 18
BO - Bolivia 17
OM - Oman 16
TN - Tunisia 16
DK - Danimarca 15
AL - Albania 14
LB - Libano 14
UY - Uruguay 14
JM - Giamaica 13
KG - Kirghizistan 13
KZ - Kazakistan 13
NO - Norvegia 13
BH - Bahrain 12
HU - Ungheria 12
BY - Bielorussia 11
PA - Panama 11
GR - Grecia 9
LV - Lettonia 9
RS - Serbia 9
SK - Slovacchia (Repubblica Slovacca) 9
AM - Armenia 8
NZ - Nuova Zelanda 8
HN - Honduras 7
HR - Croazia 7
PR - Porto Rico 7
QA - Qatar 7
SI - Slovenia 7
SN - Senegal 7
EE - Estonia 6
ET - Etiopia 6
GE - Georgia 6
LU - Lussemburgo 6
NG - Nigeria 6
NI - Nicaragua 6
SV - El Salvador 6
TT - Trinidad e Tobago 6
CY - Cipro 5
Totale 60.075
Salva come PNG Salva come JPEG
Città #
Fairfield 3.243
Ashburn 3.175
Southend 3.027
Santa Clara 2.598
Singapore 2.142
Woodbridge 1.850
Hong Kong 1.750
Houston 1.458
Chandler 1.210
Seattle 1.190
Wilmington 1.118
Cambridge 1.064
Frankfurt am Main 1.057
San Jose 1.031
Hefei 997
Jacksonville 929
Dearborn 813
Ann Arbor 785
Beijing 710
London 656
Chicago 645
Nyköping 605
Los Angeles 592
Helsinki 583
Council Bluffs 523
Ho Chi Minh City 515
The Dalles 392
New York 365
Hanoi 333
Seoul 318
San Diego 310
Milan 276
Modena 264
Princeton 238
Sofia 225
Salt Lake City 221
Izmir 209
Buffalo 202
Redwood City 193
Shanghai 190
Dallas 189
Eugene 186
São Paulo 177
Lauterbourg 174
Moscow 141
Manchester 140
Rome 140
Jakarta 135
Columbus 105
Munich 104
Elk Grove Village 103
Tokyo 98
Dublin 91
Tampa 91
Phoenix 90
Bologna 85
Da Nang 75
Toronto 74
Bremen 72
Miami 69
Boardman 68
Orem 66
Dong Ket 62
Sterling 62
Warsaw 62
Falls Church 59
Guangzhou 58
Des Moines 56
Brooklyn 55
Turin 55
Yavné 55
San Francisco 54
Atlanta 53
Chennai 52
Montreal 52
Rio de Janeiro 52
Haiphong 51
Lancaster 48
Philadelphia 47
Amsterdam 45
Stockholm 45
Mexico City 44
Denver 43
Istanbul 43
Tappahannock 42
Baghdad 41
Nuremberg 41
Norwalk 39
Dulles 38
Kilburn 38
Miano 38
Naples 37
Palermo 37
Kent 36
Newark 36
Turku 36
Redondo Beach 35
Tashkent 34
Belo Horizonte 33
Dhaka 33
Totale 42.222
Salva come PNG Salva come JPEG
Nome #
Survival of cancer patients in Italy [La sopravvivenza dei pazienti oncologici in Italia [La sopravvivenza dei pazienti oncologici in Italia] 876
Bendamustine in combination with gemcitabine and vinorelbine is an effective regimen as induction chemotherapy before autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma: Final results of a multicenter phase II study 787
Veno-occlusive disease nurse management: Development of a dynamic monitoring tool by the GITMO nursing group 695
R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lmphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi 693
Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma 628
ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. 516
T-cell lymphoma in South America and Europe. 510
Il linfoma mantellare 493
Anthracydine-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma 489
Incidence, clinical characteristics and survival of malignant lymphomas: a population-based study from a cancer registry in northern Italy. 467
Nonpegylated liposomal doxorubicin (Myocet) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EURO 18 trial 465
Transformed follicular lymphoma 448
Monocytosis has adverse prognostic significance and impacts survival in patients with T-cell lymphomas 443
A multicenter retrospective clinical study of CD5/CD10-negative chronic B cell leukemias. 416
GMP-manufactured density gradient media for optimized mesenchymal stromal/stem cell isolation and expansion. 406
Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: A 16-year follow-up study 405
Risk factors for impaired gonadal function in female Hodgkin lymphoma survivors: final analysis of a retrospective multicenter joint study from Italian and Brazilian Institutions. 403
Use of 2-(18F)fluoro-2-deoxy-D-glucose positron emission tomography in patients with Hodgkin lymphoma in daily practice: a population-based study from Northern Italy 401
Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma 388
A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: Results from the Fondazione Italiana Linfomi MCL-0208 trial 376
Treatment of indolent B-cell nonfollicular lymphomas: Final results of the LL01 randomized trial of the Gruppo Italiano per lo Studio dei Linfomi 374
Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana Linfomi 368
High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy 365
ABVD plus radiotherapy versus EVE plus radiotherapy in unfavorable stage IA and IIA Hodgkin's lymphoma: results from an Intergruppo Italiano Linfomi randomized study. 358
Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfom 356
Prognosis of follicular lymphomas 354
The length of treatment of aggressive non-Hodgkin's lymphomas established according to the international prognostic index score: long-term results of the GISL LA03 study 340
Bleomycin, epidoxorubicin, cyclophosphamide, vincristine and prednisone (BACOP) in patients with follicular non-Hodgkin's lymphoma: Results of a prospective, multicenter study of the Gruppo Italiano per lo Studio dei Linfomi (GISL) 338
Pure red-cell aplasia and epoetin therapy 335
Prognostic relevance of serum beta2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study. 335
Follicular Lymphoma International Prognostic Index 2: a new prognostic index for follicular lymphoma developed by the International Follicular Lymphoma Prognostic Factor Project 333
Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphoma 332
Outcome of frail elderly patients with diffuse large B-cell lymphoma prospectively identified by Comprehensive Geriatric Assessment: Results from a study of the Fondazione Italiana Linfomi 330
Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies 327
Anthracyclines: A cornerstone in the management of non-Hodgkin's lymphoma 324
PET-CT for staging and early response: Results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study 324
Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma. A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi 321
A Gene Expression–based Model to Predict Metabolic Response after Two Courses of ABVD in Hodgkin Lymphoma Patients 320
Phase II Study of Velcade (R) Plus Mabthera (R) In Relapsed Follicular Lymphomas. 314
Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis 314
Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. 313
A model for predicting the risk of developing mild anemia (MA) in patients with lymphoid malignancy. A study of the Gruppo Italiano Studio Linfomi (GISL) 313
Brentuximab vedotin followed by ABVD +/- radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II study 312
A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma 312
Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi 308
Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: A report from a joint Italian-Danish study 308
Prevalence and prognostic significance of sMUC-1 levels in plasma cell dyscrasias 307
Anthracycline-Fludarabine Containing Regimens with or without Rituximab in the Treatment of Advanced Follicular Lymphoma Patients 306
Age-adjusted international prognostic index is a predictor of survival in gastric diffuse B-cell non-Hodgkin lymphoma patients 306
Vinorelbine, gemcitabine, procarbazine and prednisone (ViGePP) as salvage therapy in relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL): Results of a phase II study conducted by the Gruppo Italiano per lo Studio dei Linfomi 305
Dismal outcome of t-cell lymphoma patients failing first-line treatment: results of a population-based study from the Modena Cancer Registry 305
Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies 305
Durable remission in a patient with leptomeningeal relapse of a MYC/BCL6-positive double-hit DLBCL treated with lenalidomide monotherapy 302
Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study 301
A Case-Control Study on the Role of an Antiviral Treatment with Interferon and Ribavirin after Conventional Chemotherapy in Diffuse Large B-Cell Lymphomas with Hepatitis C Virus (HCV) Infection 299
Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced hodgkin lymphoma: A study by fondazione Italiana Linfomi 299
Bendamustine salvage therapy for T cell neoplasms 296
Analysis of Frequency and Risk Factors for Developing Bisphosphonate Associated Osteonecrosis of the Jaw. 296
The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL) 295
Role of Glutathione-S-Transferase (GST) polymorphisms in patients with advanced Hodgkin Lymphoma: results from the HD2000 GISL Trial 292
High response rate and improvement of long-term survival with combined treatment modalities in patients with poor-risk primary thyroid diffuse large B-cell lymphoma: an International Extranodal Lymphoma Study Group and Intergruppo Italiano Linfomi Study 291
Decreasing incidence of gastric MALT lymphomas in the era of anti-Helicobacter pilori interventions: results from a population-based study on extranodal marginal zone lymphomas 290
ABVD versus Stanford V versus MEC in unfavourable Hodgkin's lymphoma: results of a randomised trial 287
Epoetin-induced pure red-cell aplasia (PRCA): preliminary results from the research on adverse drug events and reports (RADAR) group. 287
The role of dose size in a chemotherapy regimen (ProMECE-CytaBOM) for the first-line treatment of large B-cell lymphomas: a randomized trial by the Gruppo Italiano Studio Linfomi (GISL) 287
BISPHOSPHONATES (BP) RELATED OSTEONECROSIS OF THE JAW (ONJ): A LONG TERM FOLLOW UP (FU) OF A SERIES OF 35 CASES OBSERVED BY GISL 285
Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: A systematic review and meta-analysis of randomized clinical trials 285
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma 283
Quality of life assessment in elderly patients with aggressive non-Hodgkin's Lymphoma treated with anthracycline-containing regimens. Report of a prospective study by the Intergruppo Italiano Linfomi 282
The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study 281
Phase II Study with Fludarabine and Cyclophosphamide Plus Rituximab (FC+R) in Relapsed Follicular Lymphoma Patients. 280
CLIPI: a new prognostic index for indolent cutaneos B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11) 280
Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly “fit” patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi 276
Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma 276
A Case-Control Study on the Role of an Antiviral Treatment with Interferon and Ribavirin after Conventional Chemotherapy in Diffuse Large B-Cell Lymphomas with Hepatitis C Virus (HCV) InfectionBlood (ASH Annual Meeting Abstracts), Nov 2008; 112: 3054 275
The role of high-dose therapy and autologous stem cell transplantation in patients with primary refractory Hodgkin's lymphoma: a report from the Gruppo Italiano per lo Studio dei Linfomi (GISL) 274
Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients 274
High-dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy: long-term results. 274
Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients 274
Efficacy Controls and Long-Term Follow-Up of Patients (Pts) Treated with FC Plus Rituximab for Relapsed Follicular NHL. Session Type: Publication Only 273
A Phase II study of Bendamustine in Combination With Rituximab as Initial Treatment for Patients With Indolent non-follicular non-Hodgkin's Lymphoma 272
Watchful waiting in low-tumorburden follicular lymphoma in the Rituximab era. Results of a F2 observational 271
The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi 271
Advances in Treatment of Follicular Lymphoma 268
I tumori in Italia. Rapporto 2011: La sopravvivenza dei pazienti oncologici in Italia 267
Reply to H.J.A. Adams et al and E. Laffon et al 266
Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients 265
Long term outcome of patients with localized aggressive non-Hodgkin lymphoma treated with PROMECE-CYTABOM plus involved-field radiation therapy: a study by the Gruppo Italiano Studio Linfomi. 265
Diffuse Large B-Cell Lymphomas (DLBCL) with Hepatitis-C Virus (HCV) Infection: Incidence, Clinical Outcome and Preliminary Results of Antiviral Treatments (AVT) after Chemotherapy. 264
Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study 263
Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA/FIL study 262
ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia 262
Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in Non Hodgkin Lymphoma (NHL). A pooled data analysis of twelve clinical trials of Fondazione Italiana Linfomi (FIL) 258
Serum MUC-1 as a marker of disease status in multiple myeloma patients receiving thalidomide - Response to Mileshkin et al. 257
The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi 256
Long term results of a randomized study performed by Intergruppo Italiano Linfomi comparing Mini-CEOP vs P-VEBEC in elderly patients with diffuse large B-cell lymphoma. 256
Reply to T.P. Vassilakopoulos et al 255
Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials 254
The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale 253
Analysis of BCL-10 gene mutations in ovarian cancer cell lines. 251
Totale 33.997
Salva come PNG Salva come JPEG
Categoria #
all - tutte 237.882
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 237.882
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021390 0 0 0 0 0 0 0 0 0 0 0 390
2021/20224.667 325 538 521 270 134 271 245 297 471 365 804 426
2022/20233.849 419 393 324 330 460 504 96 396 465 97 220 145
2023/20244.005 113 207 185 229 1.442 205 411 669 78 79 89 298
2024/20259.509 313 88 141 700 1.717 1.465 723 509 1.275 557 929 1.092
2025/202619.686 1.150 893 1.690 2.483 3.003 1.416 2.386 989 1.750 1.695 1.789 442
Totale 60.806